1 study found for:    15846123 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Conditions: Lung Cancer;   Head and Neck Cancer;   Hearing Loss;   Ototoxicity;   Tinnitus;   Neuropathy
Interventions: Drug: SPI-1005 Low Dose;   Drug: SPI-1005 Middle Dose;   Drug: SPI-1005 High Dose;   Drug: Placebo

Indicates status has not been verified in more than two years